Management of Stage 2 Chronic Kidney Disease with Hypertension and Hyperlipidemia

1. Initial Laboratory Assessment

2. Blood‑Pressure Targets and Initial Therapy

3. Nephroprotective Medication Algorithm

3.1. Patients with ACR ≥ 200 mg/g (≥ 20 mg/mmol)

3.2. Patients with ACR 30–199 mg/g and Diabetes

3.3. Patients with ACR < 200 mg/g without Diabetes

4. Lipid Management

5. Monitoring Schedule

6. Nephrology Referral Criteria

7. Critical Pitfalls to Avoid

8. Additional Patient‑Centered Considerations

Guideline Recommendations for Confirming CKD and Managing Nephroprotective Therapies in Patients with eGFR ≈ 50 mL/min/1.73 m²

Diagnostic Confirmation

• Repeat serum creatinine 2–4 weeks after the initial low eGFR measurement to differentiate acute kidney injury from chronic kidney disease in adults with reduced kidney function. 9

Baseline Laboratory Assessment of CKD Complications

• Obtain baseline serum potassium, hemoglobin, calcium, phosphate, and bicarbonate to screen for CKD‑related complications that become common when eGFR falls below 60 mL/min/1.73 m². 9

ACE‑inhibitor/ARB Initiation and Monitoring

• Continue an ACE inhibitor or ARB unless serum creatinine rises > 30 % within 4 weeks of initiation; smaller increases (up to 30 %) are expected hemodynamic changes and should not trigger discontinuation. 9

Medication Dosing and Nephrotoxin Avoidance

• Review and adjust doses of all renally cleared medications because many require modification when eGFR is < 60 mL/min/1.73 m². 9
• Minimize patient exposure to iodinated contrast agents and other nephrotoxic substances to reduce the risk of further kidney injury. 9

Electrolyte and Mineral Monitoring

• Perform periodic serum potassium checks in patients receiving ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists to detect hyper‑kalaemia early. 9

Ongoing Laboratory Monitoring for CKD Complications

• Monitor hemoglobin, calcium, phosphate, and bicarbonate every 6–12 months to identify anemia, mineral‑bone disorder, and metabolic acidosis in individuals with chronic kidney disease. 9